Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

- PMLiVE

AstraZeneca officially opens new R&D facility in UK

The high-tech £1bn research and development DISC facility in Cambridge, UK will see 2,000+ scientists housed in a building designed to the highest environmental standards

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

- PMLiVE

AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising

The therapy – an mRNA-encoding vascular endothelial growth factor – looks promising for patients undergoing coronary artery bypass surgery

- PMLiVE

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

The for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

- PMLiVE

AZ’s Imfinzi boosts survival in biliary tract cancer

Positive results for Imfimzi plus chemotherapy offer hope for patients with a rare and aggressive gastrointestinal cancer

- PMLiVE

Valneva COVID-19 vaccine more effective than AZ

Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

The antibody is the only long-acting combination shown to both prevent and treat COVID-19

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

- PMLiVE

AstraZeneca requests Emergency Use Authorization from FDA for COVID-19 antibody

Phase 3 data shows the long-acting antibody combination produces a 77% reduction in the risk of developing symptomatic COVID-19

- PMLiVE

FDA grants Enhertu Breakthrough Therapy Designation in breast cancer

Phase 3 trial data presented at ESMO shows Enhertu significantly reduced the risk of disease progression or death

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links